Overview

A Study of Dulaglutide in Chinese Participants

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is a study of dulaglutide in Chinese participants. The purpose of the study is to determine how the body processes dulaglutide and how dulaglutide affects the body. This study has 2 parts: Part A - single dose of dulaglutide administered to healthy participants in 2 of 3 study periods. There is a minimum 28-day washout between periods. Part A will last approximately 16 weeks. Part B - multiple doses of dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM). Part B will last approximately 15 weeks. Doses of 0.5 milligrams (mg), 0.75 mg, and 1.5 mg of dulaglutide will be evaluated in this study.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide
Immunoglobulin Fc Fragments